call 1800 257 600 email [email protected]

Familial GIST Syndrome

Familial GIST syndrome, also known as primary familial GIST syndrome, is a rare genetic disorder that causes the development of gastrointestinal stromal tumours (GISTs), a rare type of sarcoma that forms in the lining of the gastrointestinal tract. It is caused by the genetic mutation of two tyrosine kinase genes, which are important for intracellular signals.

Familial cancer syndromes, also known as hereditary cancer syndromes, are rare conditions that cause an increased risk of cancer as the result of inherited genetic mutations in certain cancer-related genes. They can affect both adults and children, however they generally develop in people at a younger age than normal. While familial cancer syndromes are not classified as cancer, they are equally as severe and can be life-threatening as they are associated with the development of various tumours throughout the body. Having a familial cancer syndrome does not guarantee the development of cancer, however the risk of developing cancer is higher than those who do not have a familial cancer syndrome.

Familial GIST syndrome tends to affect the sexes equally, and tend to be diagnosed earlier than sporadic GISTS (often between the ages of 25-45). However, anyone can develop this disease.

Familial GIST syndrome is associated with the development of GISTs only.

A gastrointestinal stromal tumour (GIST) is a rare type of sarcoma (cancer arising from bones or soft tissues) that forms in lining of the gastrointestinal tract. More specifically, they develop in interstitial cells of Cajal (ICC), which play a critical role in the intestinal contractions required for digestion. The gastrointestinal tract is primarily responsible for food digestion and nutrient uptake, and is made up of organs such as the stomach, small intestine, and large intestine (colon). GISTs are most commonly found in either the stomach, or the small intestine.

Unlike sporadic GIST, people with this condition tend to be diagnosed at a younger age, affects both sexes equally, and often have more than one tumour.

For more information on sporadic GISTs, please refer to the Rare Cancers Australia Gastrointestinal Stromal Tumours (GIST) page.

Treatment

As GIST is the only malignancy thus far that is associated with this disease, familial GISTs are staged and graded in the same way.

If GIST is detected, it will be staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you.

Cancers can be staged using the TNM staging system:

  • T (tumour) indicates the size and depth of the tumour.
  • N (node) indicates whether the cancer has spread to nearby lymph nodes.
  • M (metastasis) indicates whether the cancer has spread to other parts of the body.

This system can also be used in combination with a numerical value, from stage 0-IV:

  • Stage 0: this stage describes cancer cells in the place of origin (or ‘in situ’) that have not spread to nearby tissue.
  • Stage I: cancer cells have begun to spread to nearby tissue. It is not deeply embedded into nearby tissue and had not spread to lymph nodes. This stage is also known as early-stage cancer.
  • Stage II: cancer cells have grown deeper into nearby tissue. Lymph nodes may or may not be affected. This is also known as localised cancer.
  • Stage III: the cancer has become larger and has grown deeper into nearby tissue. Lymph nodes are generally affected at this stage. This is also known as localised cancer.
  • Stage IV: the cancer has spread to other tissues and organs in the body. This is also known as advanced or metastatic cancer.

Cancers can also be graded based on the rate of growth and how likely they are to spread:

  • Grade I: cancer cells present as slightly abnormal and are usually slow growing. This is also known as a low-grade tumour.
  • Grade II: cancer cells present as abnormal and grow faster than grade-I tumours. This is also known as an intermediate-grade tumour.
  • Grade III: cancer cells present as very abnormal and grow quickly. This is also known as a high-grade tumour.

Once your tumour has been staged and graded, your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment is dependent on several factors, including location, stage of disease and overall health.

Treatment of Childhood GIST

Due to the rarity of GIST in childhood, there are fewer treatment options than adults with GIST. Treatment options for childhood GIST may include:

  • Surgery, potentially including:
    • Gastrectomy.
    • Complete or partial resection of the intestine.
    • Abdominoperineal resection.
    • Pancreaticoduodenectomy, also known as a Whipple procedure.
  • Targeted therapy.
  • Clinical trials.
  • Palliative care.

Treatment of GIST in adults

Adults with GIST have more treatment options that children with this disease. However, like childhood GIST, chemotherapy and radiation therapy are not often used to treat this type of cancer.

Treatment options for GISTs in adults may include:

  • Surgery, potentially including:
    • Gastrectomy.
    • Complete or partial resection of the intestine.
    • Abdominoperineal resection.
    • Pancreaticoduodenectomy, also known as a Whipple procedure.
  • Targeted therapy.
  • Watch and wait.
  • Clinical trials.
  • Palliative care.

Cancer Screening

Once a diagnosis of Familial GIST has been confirmed, implementing a targeted screening plan becomes essential due to the increased risk of developing certain cancers.  The content of this plan will vary from person to person based on the genetic mutation involved, your family’s history of cancer and the types of cancers that may be present. It will also outline the routine tests you should have and how regularly you should have them.

Screening options for Familial GIST may evolve as new technologies are developed and our understanding of the condition grows. It is essential to discuss your individual circumstances with your healthcare team to determine the most appropriate screening plan for you.

Risk factors

Familial GIST syndrome is caused by genetic mutations in two particular genes:

  • KIT (c-KIT, involved in intracellular signalling).
  • PDGFRA receptors (platelet derived growth factor receptor alpha receptors, involved in intracellular signalling).

Familial GIST syndrome is an autosomal dominant disease, which means that you have a 50% chance of developing the condition if one of your parents carries the mutation.

Symptoms

GIST may appear asymptomatic in the early stages. Adults and children with GIST may experience some of the following symptoms:

  • Blood in stool and/or vomit.
  • Abdominal pain and/or mass.
  • Bloating.
  • Fatigue.
  • Difficulties/pain when swallowing.
  • Unexplainable weight loss/loss of appetite.
  • Nausea and/or vomiting.
  • Anaemia (low levels of red blood cells).
  • Blocked intestines, which carry its own set of symptoms:
    • Abdominal cramping and/or swelling
    • Nausea and/or vomiting.
    • Diarrhoea.
    • Constipation.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have tumours associated with Familial GIST, they may order some of the following tests to confirm the diagnosis and refer you to a specialist for treatment. The tests required for diagnosis will often vary based on the symptoms present, and where the tumour(s) are suspected to be located.

  • Physical examination.
  • Genetic testing.
  • Imaging tests, potentially including:
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • PET (positron emission tomography) scan.
    • Endoscopic ultrasound.
  • Blood tests.
  • Endoscopy, most commonly a gastroscopy.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.